Loading the company…
Loading the company…
Families: Bone graft & orthobiologics, Lumbar fusion.
All companies · Product and company coverage
In 2025, Acuitive Technologies reported engagement with 3 surgeons and other clinicians in the states MedaRep covers, worth $4,523 in consulting, speaking, meals and travel for its device products, the most in New Jersey ($4,523 to 3). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New Jersey ($4,523, 3 engaged).
In the last ten years FDA made 7 decisions for Acuitive Technologies (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2023 (2). The latest was on 2024-11-06.
| Family | Decisions on record |
|---|---|
| Bone graft & orthobiologics | 1 |
| Lumbar fusion | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2024-11-06 | 510(k) | K240450 | Citrepore |
| 2023-09-20 | 510(k) | K232592 | CITRELOCK® DUO |
| 2023-02-14 | 510(k) | K221468 | Citregen Tendon Interference Screw (TIS), Citrelock Tendon Fixation Device, Citrespline and Citrelock ACL Implants |
| 2022-11-04 | 510(k) | K220833 | Citregen Tendon Interference Screw, Citrelock, Citrefix, Citrespline ACL, and Citrelock ACL |
| 2021-02-24 | 510(k) |
| K210239 |
| CITRESPLINE and CITRELOCK ACL Implants |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Acuitive Technologies.